Articles By Wayne Koberstein, Executive Editor

MAMMOTH_TREVOR MARTIN_450x300
Scientist-Founders Reshape The Bio Biz
Recently, it seems, new scientist-leaders have emerged whose backgrounds and acquired knowledge begin in science but grow to encompass business as well. Mammoth Biosciences is building, and betting, on such a model.  Continue Reading..
  • Companies To Watch: Corner Therapeutics
    2/1/2023

    Corner Therapeutics is focused on discovering new small molecules that could mimic the body’s natural immune response to generate the robust T-cell response.

  • Companies To Watch: Ocelot Bio
    1/3/2023

    Ocelot Bio is focusing a single drug on multiple complications of end-stage liver disease.

  • Biopharma Public Opinion, Pricing, Politics
    12/1/2022

    Biopharma sustainability will require the industry not shy from public opinion, but meet it head on. To win short-term battles, however impressively as with creation of the COVID vaccines, may not be enough to secure total victory.

  • Companies To Watch: iTolerance
    11/1/2022

    iTolerance is dedicated to curing diabetes and other conditions by inducing local immune tolerance in implantation.

  • Pioneering In-House, Continuous Manufacturing
    11/1/2022

    Patricia Hurter of Lyndra Therapeutics believes having an in-house continuous manufacturing capability delivers the flexibility, speed, and reliability needed for development and production of those long-acting drugs.

  • Companies To Watch: CytoAgents
    10/3/2022

    CytoAgents is combatting the broad areas of disease stemming from a common cause: cytokine release syndrome.

  • The Discovering CEO
    10/3/2022

    In the current world of biopharma companies, the discovery function covers much more than hammering out new drug entities.

  • Companies To Watch: Viking Therapeutics
    9/1/2022

    Viking Therapeutics is a broad-target contender for treating NASH in a pipeline of new drugs for metabolic and endocrine disorders.

  • Nonprofit Pursues Oncology Drugs
    9/1/2022

    RebootRX believes that many off-patent pharmaceuticals have cancer-fighting potential, but their generic status makes them unattractive commercial candidates for profit-making pharmas.

  • Companies To Watch: Priothera
    8/1/2022

    Priothera is bent on boosting the safety and effectiveness of hematopoietic stem cell transplantation for blood cancers.

  • Living Diversity, Inside Mink Therapeutics
    8/1/2022

    We sought out a biopharma enterprise where diversity always has been an operating principle, where it feeds the company’s intellectual life and creative culture, and where it is demonstrable yet still evolving.

  • Companies To Watch: Mirum Pharmaceuticals
    7/1/2022

    Mirum Pharmaceuticals: Two drugs, one FDA approved, together taking on a half-dozen rare liver diseases.

  • New Space For Bio In Transplantation
    7/1/2022

    Jasper Therapeutics and other bio companies may revolutionize hematopoietic stem cell therapy (HSCT) — a feat with profound effects on the biopharma and hospital-based hematology sectors alike.

  • Companies To Watch: CinCor Pharma
    6/1/2022

    CinCor Pharma is uncovering a great potential for combatting treatment-resistant and uncontrolled hypertension.

wayne koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.